Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Added Value of HR-pQCT in Detecting Calcium Deposits in Rheumatoid Arthritis (HAND-QCT-RA)

16 de novembro de 2026 atualizado por: Istituto Ortopedico Rizzoli

Added Value of HR-pQCT: Detecting and Characterizing Calcium Deposits Suggestive of CPPD in the Hand and Wrist of Rheumatoid Arthritis Patients (HAND-QCT-RA)

The goal of this clinical trial is to learn if a high-resolution computed tomography scan (HR-pQCT) can detect and describe calcium crystal deposits in the hands and wrists of adults with rheumatoid arthritis (RA). The main questions it aims to answer are:

  • How often does the HR-pQCT scan detect calcium crystal deposits in the hand and wrist joints of people with RA?
  • Can the HR-pQCT scan find calcium deposits that standard tests (x-rays and ultrasound) miss? Researchers will compare scan results from participants with RA to results from participants with known calcium pyrophosphate deposition (CPPD) and participants without joint inflammation.

During a single clinic visit, participants will:

  • Have standard x-rays of their hands and wrists
  • Have a routine ultrasound of their hands and wrists
  • Have an HR-pQCT scan of their wrist and finger joints, which takes about 15 to 20 minutes and uses a very low dose of radiation

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

Calcium pyrophosphate deposition (CPPD) disease is an underdiagnosed crystal arthritis that frequently mimics rheumatoid arthritis (RA) or coexists with it, particularly when presenting as chronic inflammatory polyarthritis involving the wrists and metacarpophalangeal (MCP) joints. Although synovial fluid crystal identification remains the reference standard, aspiration of small hand joints is often technically unfeasible or non-diagnostic. Consequently, diagnosis relies heavily on conventional radiography and musculoskeletal ultrasonography, both of which suffer from recognized limitations in detecting subtle or early calcifications.

High-resolution peripheral quantitative computed tomography (HR-pQCT) provides superior spatial resolution and volumetric bone microarchitecture assessment. This multicenter, cross-sectional pilot study investigates whether HR-pQCT can enhance the detection and structural characterization of CPPD-suggestive calcium deposits within the triangular fibrocartilage complex (TFCC) and 2nd/3rd MCP hyaline cartilage.

To enable combined multi-site analysis, cross-calibration between the two participating tertiary centers (IRCCS Istituto Ortopedico Rizzoli, utilizing a second-generation Scanco XtremeCT II system, and AOUI Verona, utilizing a RAR Medical Devices ArtiCAT cone-beam system) is conducted using the European Forearm Phantom (EFP; QRM AG). Scans follow harmonized volumetric acquisition protocols based on international recommendations (SPECTRA group). All imaging acquisitions (radiographs, ultrasound, and HR-pQCT) are evaluated independently and in a double-blinded manner by trained musculoskeletal radiologists and rheumatologists.

At the patient level, a participant is classified as positive if at least one calcium deposit is detected in any of the examined joints. Because each participant undergoes imaging across multiple anatomical sites (the TFCC of the wrist and the 2nd and 3rd metacarpophalangeal joints of both hands), observations from the same individual are correlated. To account for this within-subject correlation without losing anatomical detail, site-specific analyses will be conducted using mixed-effects models or generalized estimating equations (GEE).

Tipo de estudo

Intervencional

Inscrição (Estimado)

140

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Bologna
      • Bologna, Bologna, Itália, 40136
        • IRCCS Istituto Ortopedico Rizzoli - SSD Medicina e Reumatologia
    • Verona
      • Verona, Verona, Itália, 37134
        • Azienda Ospedaliera Universitaria Integrata di Verona - UO di Reumatologia

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

60 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Rheumatoid Arthritis (RA) Cohort:

  • Age ≥ 60 years
  • Diagnosis of Rheumatoid Arthritis according to 2010 ACR/EULAR classification criteria
  • Clinical diagnosis confirmed by an expert rheumatologist
  • Current or past inflammatory involvement of the hand and/or wrist
  • Written informed consent obtained

Calcium Pyrophosphate Deposition (CPPD) Cohort:

  • Age ≥ 60 years
  • Established diagnosis of CPPD based on synovial fluid crystal analysis and/or imaging findings compatible with current classification criteria
  • Current or past inflammatory involvement of the hand and/or wrist
  • Written informed consent obtained

Control Cohort (Non-inflammatory Controls):

  • Age ≥ 60 years
  • Outpatient evaluation at one of the participating centers for a condition not suggestive of CPPD, rheumatoid arthritis, erosive osteoarthritis, or other inflammatory joint diseases
  • Clinical indication for conventional radiography of the hand and/or wrist as part of routine clinical practice
  • Absence of past or present hand or wrist joint swelling suggestive of inflammatory arthritis
  • Written informed consent obtained

Exclusion Criteria:

All Cohorts:

  • Contraindications to CT-based imaging (including the inability to immobilize the hand and wrist during image acquisition)
  • Known causes of secondary CPPD (e.g., hyperparathyroidism, hemochromatosis, hypomagnesemia, hypophosphatasia)
  • Presence of hand/wrist prosthesis or osteosynthesis material interfering with image acquisition
  • Inability to provide written informed consent

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Diagnóstico
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Rheumatoid Arthritis (RA) Cohort

Patients with RA and current or prior hand/wrist involvement (n = 60).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Outros nomes:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam
Comparador Ativo: Healthy / Non-inflammatory Controls

Subjects undergoing hand/wrist imaging for non-inflammatory conditions (n = 60).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Outros nomes:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam
Comparador Ativo: CPPD Positive Control Cohort

Patients with proven CPPD disease (n = 20).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Outros nomes:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in rheumatoid arthritis
Prazo: Baseline (single imaging visit)

Percentage of participants with rheumatoid arthritis with at least one calcium deposit suggestive of CPPD detected by HR-pQCT at the triangular fibrocartilage complex (TFCC) and/or the 2nd-3rd metacarpophalangeal (MCP) joints.

Baseline (single imaging visit)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Proportion of HR-pQCT-positive cases missed by conventional imaging
Prazo: Baseline (single imaging visit)

Percentage of participants with no CPPD-suggestive calcium deposits on either conventional radiography or ultrasonography who have at least one CPPD-suggestive calcium deposit on HR-pQCT.

Baseline (single imaging visit)
Agreement between conventional radiography and HR-pQCT for CPPD-suggestive calcium deposits
Prazo: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between conventional radiography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.

Baseline (single imaging visit)
Agreement between ultrasonography and HR-pQCT for CPPD-suggestive calcium deposits
Prazo: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between ultrasonography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.

Baseline (single imaging visit)
Agreement between combined conventional imaging and HR-pQCT for CPPD-suggestive calcium deposits
Prazo: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between combined conventional imaging and HR-pQCT. A participant is classified as positive on combined conventional imaging if deposits are detected on radiography, ultrasonography, or both.

Baseline (single imaging visit)
Volume of CPPD-suggestive calcium deposits on HR-pQCT
Prazo: Baseline (single imaging visit)

Total volume of CPPD-suggestive calcium deposits per participant, measured on HR-pQCT (mm³), in participants with at least one deposit.

Baseline (single imaging visit)
Volumetric density of CPPD-suggestive calcium deposits on HR-pQCT
Prazo: Baseline (single imaging visit)

Mean volumetric density of CPPD-suggestive calcium deposits (mg HA/cm³), measured on HR-pQCT, in participants with at least one deposit.

Baseline (single imaging visit)
Anatomical distribution of CPPD-suggestive calcium deposits on HR-pQCT
Prazo: Baseline (single imaging visit)

Percentage of participants with deposits at the TFCC only, at the 2nd-3rd MCP joints only, or at both sites, among participants with at least one deposit on HR-pQCT.

Baseline (single imaging visit)

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in seronegative vs seropositive rheumatoid arthritis
Prazo: Baseline (single imaging visit)

Percentage of participants with at least one CPPD-suggestive calcium deposit on HR-pQCT, reported separately for seronegative participants (RF- and ACPA-negative) and seropositive participants.

Baseline (single imaging visit)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de janeiro de 2027

Conclusão Primária (Estimado)

30 de abril de 2029

Conclusão do estudo (Estimado)

31 de outubro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

6 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • HAND-QCT-RA

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .